# Compare PT-141 and Kisspeptin — LuvThy Peptide > A side-by-side comparison of two Sexual & Reproductive Research peptides — PT-141 and kisspeptin — across peptide class, evidence base, administration studied, regulatory status and key cautions. Where PT-141 and kisspeptin align, where they diverge, and — most usefully — where the evidence behind each one stands right now. ## The short version This page lines up [PT-141](/pt-141) and [kisspeptin](/kisspeptin) on the dimensions that matter most: what kind of molecule each is, where it has been studied, how strong that evidence is, how it was given in the research, its regulatory status, and its single most important caution. The headline: PT-141 (bremelanotide) has a completed Phase 3 program and FDA approval for one indication — HSDD in premenopausal women under prescription. Kisspeptin is fully investigational, with 29 clinical trials completed and no approved product. They target different levels of the same system: PT-141 modulates brain circuits for desire; kisspeptin modulates the upstream hormonal switch. Neither is presented here with a human dose. ## The comparison matrix | Dimension | PT-141 (Bremelanotide) | Kisspeptin | | --- | --- | --- | | Peptide class | Synthetic cyclic heptapeptide; melanocortin (MC3R/MC4R) receptor agonist | Natural neuropeptide family (KISS1 gene); KISS1R (GPR54) agonist | | Most-studied in | HSDD in premenopausal women; early Phase 2 erectile-dysfunction data | Hypothalamic amenorrhea, IVF oocyte triggering, LH stimulation in men | | Evidence base (model) | Phase 3 RCTs (n=1267) in premenopausal women with HSDD [3]; fMRI mechanistic study [2] | Phase 1/2 human trials; 29 interventional trials mapped [9]; no Phase 3 | | Administration studied | Subcutaneous injection, 1.75 mg as-needed [5]; IV used in early studies | IV infusion, subcutaneous; intranasal demonstrated in 2025 [8] | | Regulatory status | FDA-approved (as bremelanotide injection) for HSDD in premenopausal women only [5] | No approved product in any jurisdiction for any indication [9] | | Key caution | Approved only for one indication and one population; blood-pressure warning; nausea [4][5] | Tachyphylaxis with repeated/continuous dosing; all use is investigational [9][11] | ## Peptide class The two are structurally unrelated. PT-141 (bremelanotide) is a synthetic cyclic heptapeptide — seven amino acids closed into a ring by a lactam bridge — designed as an agonist at melanocortin receptors MC4R and MC3R, which are expressed in the central nervous system [7]. Kisspeptin is a family of natural neuropeptides (KISS1 gene product), ranging from KP-10 (10 amino acids) to KP-54 (54 amino acids), all sharing the conserved C-terminal Arg-Phe-amide motif that binds KISS1R [12]. PT-141 is a synthetic compound derived from alpha-MSH; kisspeptin is an endogenous signaling molecule the body already produces. ## Most-studied in Each has a primary research territory. PT-141 is most extensively studied in premenopausal women with HSDD, through the two RECONNECT Phase 3 trials; there is also meaningful Phase 2 erectile-dysfunction data from early studies in men, along with a 2022 fMRI mechanistic study in HSDD [2][3][7]. Kisspeptin research spans hypothalamic amenorrhea, IVF oocyte maturation triggering in women at high OHSS risk, LH and testosterone stimulation in healthy men, and exploratory studies in the neuroscience of sexual and romantic attraction [10][11][12]. ## Evidence base (model) This is the sharpest difference. PT-141 has completed two Phase 3 randomized controlled trials in 1267 women, a 52-week open-label extension in 684 women, and a randomized mechanistic fMRI study — a body of human evidence sufficient for FDA approval of one indication [2][3][4]. Kisspeptin has a substantial Phase 1/2 clinical program (29 interventional trials catalogued as of 2025) across multiple reproductive applications, but no Phase 3 program and no approved product [9]. One has crossed the regulatory finish line for one use; the other is still building the data package. ## Administration studied Routes in the published research differ. PT-141 (bremelanotide) is approved as a subcutaneous injection, 1.75 mg as-needed (maximum one dose per 24 hours, no more than 8 doses per month); early clinical work used intranasal and intravenous routes [5]. Kisspeptin has been administered intravenously (continuous infusion and bolus), subcutaneously, and — in a 2025 first demonstration — by intranasal spray, which produced LH responses comparable to or greater than IV bolus in some groups [8]. ## Regulatory / WADA status The regulatory positions are meaningfully different. Bremelanotide is a prescription pharmaceutical, FDA-approved for HSDD in premenopausal women; material sold as "PT-141 research chemical" sits entirely outside that approval, with no regulatory oversight [5]. Melanocortin receptor agonists fall under WADA's non-approved-substances framework (S0) for compounds without regulatory approval in the relevant context — athletes should consult current WADA guidance. Kisspeptin has no approved product from any major regulator for any indication; it is not specifically listed on the WADA Prohibited List by name, but as a peptide hormone class it is subject to anti-doping regulation and athletes should treat it accordingly [9]. ## Key caution Each compound's defining caution is distinct. For PT-141, it is the boundary of approval: bremelanotide is approved for one diagnosis in one population under prescription, and everything outside that boundary — including the research-chemical form — is unapproved and unregulated; the blood-pressure warning and common nausea are concrete safety concerns within even the approved use [5][4]. For kisspeptin, it is tachyphylaxis: the KISS1R desensitizes rapidly with sustained or repeated stimulation, so the receptor that should be turned on is instead turned off, and all use is investigational under medical supervision with pharmaceutical-grade material [9][11]. Reading them together, the lesson is: different levels of the same system, different evidence stages, and a clear need to read carefully. --- A clinician's-briefing digest of the sexual and reproductive research-peptide literature — citations sourced, never prescribed.